Opinion · VigiEye View Regulatory

Your FDA approval package is now a global filing asset. Plan it like one

FDA's Global Reliance Disclosure Program turns the agency's review file into an export. Regulatory teams that treat it as an afterthought will lose the main benefit, and could take on new risk.

VigiEye editorial · Wed 18 Nov 2026

A quiet announcement with a long reach

On 17 November FDA launched the Global Reliance Disclosure Program. It lets applicants obtain minimally redacted FDA approval packages to support filings with foreign regulators. It starts with PEPFAR tentative approvals and widens to novel drugs and biologics in January 2027.

The PEPFAR start is the easy part to dismiss. The January 2027 widening is the part that should change how regulatory teams work. From then on, the document that explains why FDA approved a product can travel with the sponsor into other jurisdictions. My position is that sponsors should stop treating the US approval package as the end of the US story. It is the first exhibit in every later filing.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this column is based on

Opinion: this column argues a position. Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →